Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression

被引:28
作者
Wheatland, R [1 ]
机构
[1] Endocrine Res Project, Santa Cruz, CA 95060 USA
关键词
D O I
10.1016/j.mehy.2005.02.031
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Dysregulation of the hypothalamic-pituitary-ad renal (HPA) axis is a commonly recognized feature of many pathological conditions. Abnormal adrenal responses to experimental manipulation have been welt documented in patients suffering from chronic fatigue syndrome, anorexia nervosa and major depression. Yet no defect of any single organ, gland or brain region has been identified as a cause of these abnormalities. The disruption of the HPA axis that occurs in these conditions can be understood if an interfering factor is present in these patients. Evidence indicates that this interfering factor is adrenocorticotropin hormone (ACTH) autoantibodies. Chronic high levels of ACTH autoantibodies wilt significantly disrupt the HPA axis and force the body to compensate for an impaired cortisol response. The resulting effect of chronic ACTH autoantibody interference is the manifestation of adrenocortical insufficient symptoms and psychological disturbances. Some symptoms of chronic fatigue syndrome, anorexia nervosa and major depression, such as anxiety, are the adverse effects of mechanisms compensating for less effective ACTH due to autoantibodies. Furthermore, these patients engage in extraordinary behaviors, such as self-injury, to increase their cortisol. levels. When this compensation is inadequate, symptoms of adrenocortical insufficiency appear. Corticosteroid supplements have been demonstrated to be an effective treatment for chronic fatigue syndrome, anorexia nervosa and major depression. It allows the patients to have the corticosteroids they require for daily functioning and daily stressors. This therapy wilt relieve the patients of their symptoms of adrenocortical insufficiency and permit their cortisol-stimulating mechanisms to operate at levels that wilt not cause pathological problems. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:287 / 295
页数:9
相关论文
共 54 条
[1]  
AMSTERDAM JD, 1983, AM J PSYCHIAT, V140, P907
[2]  
ARANA GW, 1995, AM J PSYCHIAT, V152, P265
[3]  
ARANA GW, 1991, J CLIN PSYCHIAT, V52, P304
[4]  
BANKI CM, 1987, AM J PSYCHIAT, V144, P873
[5]   NEUROENDOCRINE RESPONSES TO D-FENFLURAMINE AND INSULIN-INDUCED HYPOGLYCEMIA IN CHRONIC FATIGUE SYNDROME [J].
BEARN, J ;
ALLAIN, T ;
COSKERAN, P ;
MUNRO, N ;
BUTLER, J ;
MCGREGOR, A ;
WESSELY, S .
BIOLOGICAL PSYCHIATRY, 1995, 37 (04) :245-252
[6]   The use of dexamethasone in elderly patients with antidepressant-resistant depressive illness [J].
Bodani, M ;
Sheehan, B ;
Philpot, M .
JOURNAL OF PSYCHOPHARMACOLOGY, 1999, 13 (02) :196-197
[7]  
Bouwer C, 2000, DEPRESS ANXIETY, V12, P44, DOI 10.1002/1520-6394(2000)12:1<44::AID-DA6>3.0.CO
[8]  
2-C
[9]  
BUTLER PD, 1990, J NEUROSCI, V10, P176
[10]   Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial [J].
Cleare, AJ ;
Heap, E ;
Malhi, GS ;
Wessely, S ;
O'Keane, V ;
Miell, J .
LANCET, 1999, 353 (9151) :455-458